Sarepta’s Elevidys makes advances towards expanded DMD label
Despite failing its primary endpoint in the EMBARK confirmatory study, Elevidys’ efficacy supplement has gained FDA priority review.
Despite failing its primary endpoint in the EMBARK confirmatory study, Elevidys’ efficacy supplement has gained FDA priority review.
What's Your Reaction?
